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ABSTRACT 
INTRODUCTION: Lichen planus is an immunologically mediated skin and 
mucous membrane disease, which can affect oral mucosa, the skin, genitalia, hair 
follicles, nails, esophagus, urinary tract, nasal mucosa, larynx and even the eyes.
 
Lichen planus has been found in patients with Hepatitis C virus related liver 
disease, with variable frequency in several studies till date. However an association 
between HCV infection and lichen planus is uncertain because prevalence of HCV 
infection in patients with lichen planus varies considerably from one geographic 
area to another. If there is a true association, lichen planus in certain populations 
may be used as a sign of HCV infection in asymptomatic patients, leading to early 
diagnosis and treatment, and a better prognosis of infected patients. 
AIM AND OBJECTIVE: To study the association between Lichen planus and 
Hepatitis C infection in this geographical region. 
 
MATERIALS AND METHODS: 
PLACE: GOVT. STANLEY MEDICAL COLLEGE, CHENNAI 
TYPE: Prospective, Observational 
TIME: July 2013 to June 2014 
SAMPLE SIZE: 100 lichen planus patients, 100 controls 
 
RESULTS AND CONCLUSION: The present study shows no association 
between lichen planus and hepatitis C infection. Based on this result, it can be 
concluded that anti-HCV antibody testing is not necessarily required in lichen 
planus patients having no risk factors for HCV infection in this geographic region. 
 
KEY WORDS: Lichen Planus, Hepatitis C virus 
  
 
 
 
 
INTRODUCTION 
  
  
 Lichen planus is a chronic inflammatory disease of skin and 
mucosa, which exhibits distinct morphology and histopathology. It can 
affect skin, genitalia, hair follicles, nails, oral mucosa, nasal mucosa, 
esophagus, larynx and eyes.
1 
Out of enormous number of associations 
reported, Hepatitis C virus (HCV) infection is one of them. 
 Lichen planus was first described by Hebra, but later named by 
Erasmus Wilson in 1869. The word Lichen comes from Greek word 
‘leichen’, which means tree moss.1 It refers to a unique group of flower-
less vegetation. And the word Planus (Latin- ‘planus’) means flat. Lichen 
planus is a self-limiting condition which commonly affects middle-aged 
adults. It involves skin, mucous membranes, hair and nails. 
 In skin, the hallmark of lichen planus is its clinical manifestation as 
itchy, violaceous, flat-topped, glistening, polygonal papules and plaques, 
most commonly occurring over flexor aspect of extremities, especially 
wrist. Nail changes include ridging, thinning and sub-ungual 
hyperkeratosis. Scalp involvement leads to scarring alopecia. 
 
 
  
Variants of lichen planus include hypertrophic, atrophic, actinic, 
follicular, bullous, annular, linear and lichen planus pigmentosus.
1
 Oral 
lichen planus has low tendency for spontaneous regression as compared 
to cutaneous type. Clinically, oral lichen planus can be of reticular, 
bullous, plaque, erosive or atrophic types. 
 Many factors are reported as far as the etiology of lichen planus is 
concerned. Hepatitis C virus infection is one of them. The association 
between lichen planus and Hepatitis C infection was first reported in 
1991.
3,12
 Since then, many studies have supported this view and have 
suggested the importance of liver monitoring in patients of muco-
cutaneous lichen planus. 
 As HCV infection is usually indolent
4
, patients may present only in 
late stages of the disease with serious complications like cirrhosis and 
chronic liver disease. So, if association between lichen planus and HCV 
infection is found to be true, screening of patients with lichen planus may 
help in early diagnosis, treatment as well as decreased transmission of 
HCV infection in asymptomatic individuals. 
 
  
But on the contrary, if the same is not a true association, screening 
of lichen planus patients may result in unnecessary use of medical 
resources, along with financial and mental trauma to those being tested. 
 The study will help in further supporting this fact and hence 
moving a step closer to frame the guidelines regarding HCV screening in 
lichen planus patients. 
 Diagnosis of lichen planus is mostly clinical, but can be confirmed 
by histopathology in doubtful cases. Treatment options include 
corticosteroids, retinoids, immunosuppressive agents and other newer 
agents. 
  
  
 
 
 
AIMS AND OBJECTIVES 
  
  
 
 
 
1. To study the association between lichen planus and Hepatitis  
C virus infection in this particular geographical region. 
2. To study various clinical presentations of lichen planus. 
 
 
 
 
 
 
 
 
  
 
 
 
REVIEW OF LITERATURE 
 
 
 
 
 
 
 
 
 HISTORICAL ASPECTS 
 The name ‘lichen planus’ was given by Erasmus Wilson in 1869. 
The term ‘lichen’ was applied because of its clinical presentation of flat-
topped lesions similar to dry excrescences of symbiotic vegetation known 
as lichen. 
 Hebra described the condition as Leichen Ruber/ Lichen Ruber 
Planus.
1 
Hallopeau (1887) and Darier (1892) considered it as a 
modification of lichen sclerosus et atrophicus because of morphological 
similarity.
5 
Kaposi described first variant of the disease in 1892 and used the 
term Lichen Ruber Pemphigoides for widespread bullous eruption 
complicating typical lichen planus.
56 
Louis Frederick Wickham (1895) 
described characteristic whitish striae on the top of flat papules.
7,8 
 Lichen planopilaris (Pringle, 1895) and Follicular lichen planus 
(Silver et al) are clear terms that describe clinical syndrome of lichen 
planus associated with cicatricial alopecia.
9 
Darier (1909) described 
histopathological findings and attributed the appearance of Wickham’s 
striae to increase in granular cell layer.
1,5 
 
  Graham Little (1915) reported scalp involvement in lichen 
planus.
41
 Schreiner (1930) divided bullous lichen planus into lichen 
planus vesiculosus and lichen planus pemphigoides. Niles (1941) 
described actinic lichen planus.
6
 
Thyresson and Meberger demonstrated colloid bodies at dermo-
epidermal junction and suggested these to be degenerating epithelial 
cells.
5,8
 Glickman (1964) attributed pallor, which produces appearance of 
Wickham striae, to the absence of papillary capillaries in centre of the 
lesion. But, Ryan in 1966 attributed violaceous hue, which surrounds the 
areas of pallor, to the radially arranged capillaries.
5,8 
Pinkus and Mehregan (1969) suggested damage to the basal cell 
layer as basic histopathological feature.
8 
Zaias (1970) described histology 
of nail lesions in lichen planus.
6 
Lichen planus-Lupus erythematosus overlap was first described in 
1970.
55
 Aronson and Soltani reported triad of lichen planus, myasthenia 
gravis and thymoma in 1978.
6
 Further, Pelisse et al described Vulvo-
vaginal gingival syndrome
10
 in 1982.
 
 
 
 In 1989, perforating variant of lichen planus (Hanav and Sengel) 
and another entity called Grinspan syndrome (Triad of lichen planus, 
hypertension and diabetes mellitus) were described.
11
 Cribier et al 
described male equivalent of vulvo-vaginal-gingival syndrome as Peno-
gingival syndrome
10
 in 1993. 
Hepatitis C virus was discovered as a single stranded RNA virus in 
1989 and testing for anti-HCV antibodies started from 1991. Thereafter, 
association between lichen planus and hepatitis c virus infection came to 
light.
3 
Hard and Humberg used penicillin for treating lichen planus in 
1954. Sehgal et al reported effectiveness of griseofulvin (1971) and 
levamisole (1978) in recalcitrant lichen planus. Many other drugs and 
modalities like isotretinoin, dapsone, phenytoin, cyclosporine and PUVA 
have been tried with variable success in treating lichen planus.
6 
 
 
 
 
 EPIDEMIOLOGY 
 Incidence: Exact incidence and prevalence of the disease is not 
known. But it has been estimated to be about 1% of general population 
worldwide.
6
 Studies have shown the incidence to range from 0.38% (in 
India)
14 
to 1.2%. About 15% cases have lesions confined to mouth.
33 
Lichen planus has no racial predisposition. 
 Age/Sex: Females are usually affected in sixth decade. But males 
have an earlier age predisposition (fourth decade). The disease is less 
common at extremes of age. There is no sex predilection, except female 
preponderance in some studies.
6,13 
 Seasonal Variation: Increased frequency of cases has been reported 
in rainy season.
15 
 Genetics: Association with HLA-B7, -Aw19, -B18 and -Cw8 has 
been found in familial cases and HLA-A3, -A5, -A28, -B8, -B16 and -
Bw35 have been reported in non-familial cases of lichen planus.
1,20 
HLA-
DQ1 may be associated with resistance to the disease.
16 
Oral lichen 
planus is associated with HLA-B8 and carbohydrate intolerance in Jews 
has been linked to HLA-28.
17 
 Symptomatic lichenoid reactions: These are associated with 
exposure to paraphenylene diamines, methacrylic acid esters, gold, 
nickel, musk ambrette and aminoglycoside antibiotics.
58 
PATHOGENESIS 
 Lichen planus is immunologically mediated, with cell-mediated 
immunity playing a major role and humoral immunity playing a 
secondary role in the pathogenesis. Both CD4+ and CD8+ T-cells have 
been found in lesional skin, but progression of disease leads to 
preferential accumulation of CD8+ cells. Another type of lymphocytes in 
the infiltrate of lichen planus is CD45RO+ (memory) cells, which are not 
found in normal skin.
1 
Epithelial-lymphocyte interaction in lichen planus involves antigen 
recognition, cytotoxic lymphocyte activation and keratinocyte apoptosis.
1 
Antigen recognition: CD8+ cytotoxic T-cells within epithelium and 
those adjacent to basal keratinocytes recognize lichen planus- specific 
antigens associated with major histocompatibility complex (MHC) class-I 
on lesional keratinocytes. Exact nature of antigen is unknown but it may 
be an autoreactive peptide or an exogenous factor like altered protein, 
 infectious agent (HCV, HSV, HIV or Helicobacter pylori), drug, contact 
allergen or dental amalgam (mercury and gold).
1 
Role of T-helper (CD4) cells in lichen planus is unclear, but it is 
proposed that these cells are activated via antigen-presenting cells like 
Langerhans cells or epidermal keratinocytes, in association with members 
of MHC class-II, and may propagate CD8+ cells through release of 
cytokines.
1 
Lymphocyte activation: Activated cytotoxic lymphocytes undergo 
oligoclonal proliferation and release cytokines and chemokines like 
interleukins (IL-2, 4, 6, 10 and 1β), interferon (IFN-γ), tumor necrosis 
factor (TNF-α) and transforming growth factor (TGF-β). Both Th1 and 
Th2 products (pro-inflammatory and anti-inflammatory) are released 
simultaneously,
1
 and balance between these determines the clinical 
behavior of the disease. These cytokines upregulate the expression of 
specific keratin genes like K1, K6, K10, K16 and K17. In contrast, K4 
and K13 are reduced. 
T-cells secrete RANTES (regulated upon activation, normal T-cell 
expressed and secreted), which leads to mast cell degranulation and 
consequent release of TNF-α, and this again upregulates RANTES 
secretion. This process may contribute to chronicity of the disease.
21 
  
IFN-γ produced by T-helper cells during antigen recognition stage 
induces keratinocytes to produce lymphotoxin-α and TNF-α and to up-
regulate MHC class-II, thus increasing interactions with T-helper cells. 
IFN-γ also up-regulates expression of intercellular adhesion molecule 
(ICAM-1) and vascular cell adhesion molecule (VCAM-1) by basal 
keratinocytes and langerhans cells.
1 
ICAM-1 is a ligand for the β2-
integrin, leukocyte function-associated antigen-1, on the surface of 
lymphocytes. The ligands for β1-integrin of lymphocytic surface are 
laminin-5 and collagen- IV and –VII, which are also increased in lichen 
planus. These interactions also increase the association of lymphocytes 
with the basement membrane. Further, integrin-α3 is present on activated, 
skin-homing T-cells and it leads these effector cells to epidermal-dermal 
interface and basement membrane (which contains laminin-5, the ligand 
for this integrin). 
Finally, this close interaction between lymphocytes and basement 
membrane leads to alteration in extracellular matrix (through matrix 
metallo-proteinase) causing apoptosis, basement membrane disruption, 
reduplication and sub-epidermal cleft formation.
2 
 
  
Keratinocyte apoptosis: Exact mechanism is unclear but possible 
ones are (1) binding of TNF-α (secreted by T-cells) to TNF-α R1 receptor 
on keratinocyte surface, (2) binding of T-cell surface CD95L (Fas ligand) 
on CD95 (Fas) of the keratinocytes, (3) over-expression of bone 
morphogenic protein (BMP-4) in mucosal lichen planus leading to 
apoptosis of oral epithelial cells
18
, (4) entry of granzyme-B (secreted by 
T-cells) into keratinocyte through perforin-induced membrane pores 
initiating caspase activity, and (5) loss of basement membrane-derived 
cell survival signal (basement membrane disruption), which normally 
prevents apoptosis. 
Association with dental amalgam: Mercury in dental amalgam 
fillings may be a causative agent in cases of oral lichen planus.
54 
Increased risk of lichen planus is due to corrosion of amalgam and the 
galvanic effect from dissimilar dental material in continuous contact with 
oral mucosa (called as Bimetallism). 
 
 
 
  
CLINICAL FEATURES 
 Classical cutaneous lesions in lichen planus are plain-topped, 
violaceous/purplish, polygonal, pruritic papules and plaques of varying 
sizes. Highly characteristic Wickham’s striae (fine whitish reticulated 
networks) can be observed with hand-lens after applying oil, xylene or 
water over the surface of lesions.
7,8,20 
 Lesions are distributed in a bilaterally symmetrical fashion over 
flexural areas of wrists, arms and legs. These are grouped and tend to 
coalesce. Thighs, trunk, back and neck may also be involved in later 
stages. Face is usually spared and palmo-plantar involvement is 
unusual.
1,6 
 In active stage of the disease, any injury/scratching/trauma leads to 
an isomorphic phenomenon named as Koebner’s isomorphic 
phenomenon.
20
 Lichen planus usually heals with hyperpigmentation
1,19,20
 
which is more prominent in darker individuals. 
 
 
  
CLASSIFICATION
1,20
 
 Morphology: Hypertrophic, Atrophic, Erosive/ulcerative, Bullous, 
Annular, Linear, Follicular, Actinic, Guttate, Perforating, Lichen planus 
pigmentosus 
 Site: Mucosa, Nails, Scalp, Inverse, Palmo-plantar 
 Special Forms: Lichen planus pemphigoides, Keratosis lichenoides 
chronica, Lichenoid drug eruption, Lichenoid dermatitis, Lichenoid 
keratosis, Lichen planus- Lupus erythematosus overlap syndrome, 
Lichenoid reaction of GVHD & Malignant transformation. 
  
ANNULAR LICHEN PLANUS: Occuring in about 10% cases, 
this form presents as arcuate grouping of papules, which develop rings or 
peripheral extension of clustered papules with central clearing. Annular 
lichen planus is usually seen over penis and scrotum and is more common 
in blacks.
1,19 
  
 
  
LINEAR LICHEN PLANUS: Spontaneous isolated lesions of 
lichen planus (not as part of Koebner’s phenomenon), measuring several 
inches, occur in linear distribution. Sometimes these may involve whole 
length of a limb. This form is usually seen in childhood. Differential 
diagnoses include nevus unius lateris, lichen striatus and linear psoriasis. 
A zosteriform pattern has been described and lichen planus can 
even occur at site of healed herpes zoster.
22
 Multiple linear lesions along 
the lines of Blaschko may also occur (due to post-zygotic somatic 
mutations).
23,44 
HYPERTROPHIC LICHEN PLANUS (Lichen planus 
verrucosus): Considered as the most pruritic variant of lichen planus, 
lesions usually occur over shins and interphalangeal joints, and are 
thickened, hyperkeratotic and elevated, with occasional verrucous 
plaques. These heal with atrophic scar. Common association is with 
chronic venous insufficiency.
20 
Keratoacanthoma
40
 and squamous 
carcinoma have been reported to arise from long-standing lesions.
24,25 
 
 
  
ATROPHIC LICHEN PLANUS: This rare form is usually seen 
over lower extremities and trunk and is characterized by few well-
demarcated papules or plaques with central superficial atrophy.
20 
Atrophy 
may be a result of faded annular type or resolved hypertrophic type of 
lichen planus. Morphology may resemble lichen sclerosus et atrophicus 
or guttate morphea. 
 
BULLOUS LICHEN PLANUS: Vesicles and bullae may develop 
within the pre-existing lesions of any type of lichen planus during acute 
flare-up. These develop commonly over lower extremities and are 
associated with mild constitutional symptoms. 
Familial type of bullous lichen planus
26
 is a rare autosomal 
dominant disorder. Onset is bimodal, with peaks at 1-3 years and 13-17 
years of age. Lesions are most common over shins. Earlier onset and 
widespread distribution differentiates it from the non-familial type. 
 
 
 LICHEN PLANUS PIGMENTOSUS: It is seen among darker 
races and Latin Americans, and is not associated with typical papules of 
lichen planus.
20 
Asymptomatic, hyperpigmented dark-brown macules are 
seen in sun-exposed areas and flexural folds.
27
 Mucosa, palms and soles 
are never involved. Erythema dyschromicum perstans (Ashy dermatosis 
of Ramirez) bears significant similarity to lichen planus pigmentosus. 
Case has been reported in association with Acrokeratosis of Bazex.
46 
EROSIVE/ULCERATIVE LICHEN PLANUS: This rare variant 
is clinically seen as painful bullae and ulcerations of feet.
48
 Permanent 
loss of toe nails, webbing of toes and cicatricial alopecia of scalp are 
usually present. Squamous cell carcinoma has been reported. Other rare 
associations of erosive lichen planus are Castleman’s lymph node 
hyperplasia and malignant lymphoma. 
LICHEN PLANO-PILARIS (Follicular lichen planus/ lichen 
planus acuminatus or peripilaris): It may occur alone or may co-exist with 
other variants. Keratotic, spiny, hyperpigmented, follicular papules are 
seen over trunk and extremities. Involvement of scalp can lead to 
cicatricial alopecia. Inflammatory infiltrate targets stem cell containing 
region (infundibulo-isthmic) of follicles.
28 
 Associations reported are dermatitis herpetiformis
52
 and etanercept 
therapy.
43 
Graham-Little-Piccardi-Lassueur syndrome
41 
(or Graham-
Little-Feldman) is the triad of follicular lichen planus of skin (lichen 
planus spinulosus) and/or scalp, multifocal cicatricial alopecia of scalp 
and non-scarring alopecia of axillary and pubic areas. Some variants of 
lichen plano-pilaris have also been described, like pseudopeladic form of 
Brocq
53
, tumidus form with oval plaques of mastoid area, post-
menopausal frontal fibrosing alopecia
42
 and lichen plano-poritis.
29 
 
LICHEN PLANUS PEMPHIGOIDES: It is a controversial entity 
in which there is co-existence of bullous pemphigoid and lichen planus. 
Proposed mechanism is that basal cell keratinocyte damage by 
lymphocytes unmasks hidden antigenic determinants, which leads to 
autoantibody formation through epitope spreading. These antibodies react 
with BP-180 kDa and BP-200 kDa antigens.
30 
Clinically, tense blisters 
occur over lesional as well as normal uninvolved skin, usually over 
extremities. It may be associated with paraneoplastic pemphigus
57
 and 
PUVA therapy.
31 
 
 ACTINIC LICHEN PLANUS: Also called as lichen planus 
actinicus, lichen planus subtropicus, summer time actinic lichenoid 
eruption, lichen planus atrophicus annularis and lichenoid 
melanodermatitis, this form is seen during the spring and summer season, 
usually affecting children and young adults in tropical countries.
32,45 
Sunlight is considered as a predisposing factor. In contrast to the classical 
lichen planus, this variant is characterized by minimal itching and scaling. 
Lesions occur over exposed areas of face, hands, arms and nape of neck 
and are annular with violaceous colour, surrounded by a thready, rolled, 
hypopigmented edge showing well-defined borders. 
GUTTATE (ERUPTIVE) LICHEN PLANUS: Widely scattered 
discrete lesions resembling guttate psoriasis are seen. 
EXFOLIATIVE, EXANTHEMATOUS FORMS: These may be 
seen as a part of manifestations of lichenoid drug reactions and are very 
rare. 
INVISIBLE LICHEN PLANUS (de Gougerot): Inflammatory 
phase is minimal and lesions are visible only under Woods lamp.
1 
 
 MUCOSAL LICHEN PLANUS: Various mucosal surfaces in the 
body like those of mouth, vagina, esophagus, conjunctiva, urethra, anus, 
nose, tympanic membrane or larynx may be involved. It may be the sole 
manifestation in 20-30% cases of lichen planus. 
Oral mucosa is involved in about 60-70% of patients with lichen 
planus. Prolonged emotional stress may be a precipitating factor 
(psychosomatization).
34 
Humoral autoimmunity (Anti-desmoglein1 and 
anti-desmoglein3 antibodies in case of erosive variant of oral lichen 
planus) seems to be involved in the pathogenesis of oral lichen planus.
37 
Buccal, gingival and glossal mucosae are commonly affected. Lesions are 
bilaterally symmetrical and are usually asymptomatic. Differential 
diagnoses include leukoplakia, candidiasis, smoker’s patches and white-
sponge naevi. Gingival stomatitis or desquamative gingivitis may be the 
sole presentation in some cases. 
Various types of oral lichen planus include reticular, bullous, 
plaque-type, erosive and atrophic.
35
 Out of these, the reticular type is 
commonest, which is seen as atrophic plaques with raised whitish streaks 
in a lacy pattern over buccal mucosa. Plaque-type of oral lichen planus is 
seen as multiple raised white plaques, usually over buccal mucosa and 
tongue. Erosive type is common in elderly patients and is extremely 
 painful. It is more prone to develop squamous cell carcinoma. Low rate or 
complete absence of apoptosis in inflammatory infiltrate and epithelial 
cells in cases of oral lichen planus potentiates the molecular defects in 
epithelial cells, leading to carcinogenesis.
38 
Higher expression of cyclo-
oxygenase-2 is also postulated as a cause for carcinoma.
50 
Most 
commonly, tongue is the site for malignancy, followed by buccal mucosa. 
Concurrent tobacco use and long duration of the disease are the risk 
factors.
1 
Lesions may extend to posterior pharynx, larynx and 
esophagus.
36 
Atrophic type may occur simultaneously with erosive or 
reticular types, over gingival mucosa. 
Genital: Male genital involvement in lichen planus has been 
described in about 25% of cases with typical lesions. Glans and shaft of 
penis are commonly involved. Most of the lesions are of annular 
morphology and are symptomatic with pruritus and burning sensation. 
Females are affected in peri- and post-menopausal period. Patches 
of leukoplakia or erythroplakia are seen, occasionally with generalized 
desquamative vaginitis. Painful vulval introital erosions with white lacy 
reticular borders extending into vagina are characteristic. Marked 
structural changes like loss of labia minora, clitoral burying and vaginal 
 adhesions may result. Anal mucosal lesions present as hyperkeratosis and 
fissuring. 
Decreased antioxidant defense of basal cells results in oxidative 
stress and damages the cellular lipids, proteins and DNA. This initiates 
the immune process leading to lesions of vulval lichen planus.
39 
Vulvovaginal-gingival syndrome is combination of desquamative 
gingivitis and vulvovaginal erosive lichen planus, leading to burning 
pain, dyspareunia and vaginal discharge.
10 
Cicatricial conjunctivitis may occur if lichen planus involves 
conjunctiva.
51 
Direct immunofluorescence can differentiate between 
ophthalmic lichen planus from cicatricial pemphigoid. 
PALMO-PLANTAR LICHEN PLANUS: This acral variant is 
rare. Lesions lack characteristic shape and colour of lesions elsewhere 
and are firm to touch.
47
 Erythematous scaly plaques are seen on the 
internal plantar arch and yellowish compact keratotic papules are present 
on lateral margins of fingers and hand surfaces. Pruritus may be absent. 
Clinically, there may be close resemblance to psoriasis vulgaris, warts, 
callosities, porokeratosis or secondary syphilis. Rarely, chronic ulcerative 
variant of lichen planus can occur over soles. 
 LICHEN PLANUS OF NAILS: Nail is involved in 10-15% of 
patients. Lichen planus may be limited to nails or it may be a part of 
widespread disease. Finger nails are more commonly involved.
49 
Thinning, longitudinal ridging and onychoschizia are commonest 
findings. Onycholysis, onychorrhexis, sub-ungual hyperkeratosis, 
trachyonychia and even anonychia (especially toe nails) may also occur. 
Pterygium (forward growth of eponychium with adherence to proximal 
nail plate) is a classic finding, indicating severe nail matrix involvement. 
Pup-tent sign occurs because of nail bed involvement, leading to 
elevation of nail plate. In children, idiopathic atrophy of the nails has 
been associated. 
LICHEN PLANUS OF SCALP: In typical cases, keratotic 
follicular papules coalescing to form plaques are seen over scalp. 
Perifollicular erythema and acuminate keratotic plugs are characteristic. 
Women are more commonly affected. End stage leads to extensive 
scarring alopecia, because of which various terms are used like lichen 
plano-pilaris and folliculitis decalvans et atrophicus. 
INVERSE LICHEN PLANUS: Lesions occur in flexural areas 
like axillae, groin, infra-mammary and rarely, popliteal and antecubital 
areas.
1 
 LICHENOID DRUG REACTIONS: These develop after 
ingestion, inhalation or contact with certain drugs, with lesions occurring 
symmetrically over trunk and extremities. Latency period ranges from 
weeks to months. Mucosae are usually spared. Resolution occurs in 3-4 
months, except in gold-induced eruption, which may take up to 2 years to 
resolve, after stopping the drug. 
Common drugs causing lichenoid eruptions include gold, mercury, 
quinine, mepacrine, demeclocycline, furosemide, thiazides, NSAIDs, 
PUVA therapy, isotretinoin, amlodipine, ethambutol, carbamazepine, 5-
fluorouracil, streptomycin, isoniazid, pyrazinamide, methyldopa, 
propranolol, enalapril, captopril, clopidogrel and interferon/ribavirin 
treatment of hepatitis C. Penicillamine can cause oral lesions.
1,20 
LICHEN PLANUS-LUPUS ERYTHEMATOSUS OVERLAP: 
Classic lesions of lichen planus are absent. Atrophic hypopigmented 
patches and plaques having livid red or blue-violet colour, along with 
telangiectasia, occurring usually over extremities are characteristic. Some 
cases may progress to systemic lupus erythematosus. The disease runs a 
chronic course and is resistant to therapy. Histologically features of both 
lichen planus and lupus erythematosus are present. 
 
  
KERATOSIS LICHENOIDES CHRONICA (NEKAM’S 
DISEASE): This rare dermatosis (also known as lichen ruber 
moniliformis or orokeratosis striata lichenoides) clinically presents as 
violaceous or erythematous, verrucous papules and nodules arranged in 
linear or reticular pattern over hands, feet, extremities and buttocks.
1,59
 
Lesions are covered with hyperkeratotic plug. Oral manifestations include 
recurrent aphthous ulcers and erythrokeratotic papules. 
LICHEN PLANUS AND MALIGNANCY: Risk factors for 
malignant transformation include long-standing disease, erosive and 
atrophic variants and tobacco usage. Incidence of squamous cell 
carcinoma is reported in 0.5-5% of cases with oral lichen planus. Most 
common site for malignancy is tongue, followed by buccal mucosa, 
gingiva and lip.
1 
Lesions occur as indurated, non-healing ulcers or 
exophytic lesions with keratotic surface. Nodal metastases and death can 
occur in more advanced cases. 
 
 
 LICHENOID GRAFT VERSUS HOST DISEASE: Lichenoid 
eruption occurs over trunk, lower extremities, palms and soles as a part of 
chronic GVHD. Xerostomia and oral ulcers may also occur. 
 
LICHENOID KERATOSIS: (Solitary lichen planus or Lichen 
planus-like keratosis)
63
 This condition probably represents inflammatory 
stage of involuting solar lentigines.
64 
It presents as a non-pruritic, bright 
red to brown, scaly, papule or plaque over sun-exposed areas of trunk and 
extremities, which is almost always solitary, though multiple lesions have 
also been reported. Histologically, parakeratosis, presence of eosinophils 
and plasma cells in the infiltrate, are seen in addition to features of lichen 
planus. Frequent associations are seborrheic keratosis, actinic keratosis 
and solar lentigines. 
 
 
 
 
 
  
ASSOCIATIONS 
Cutaneous:
60,65 
Alopecia areata, Vitiligo, Systemic lupus erythematosus, Morphea, 
Dermatomyositis, Lichen sclerosus et atrophicus, Pemphigus vulgaris and 
Paraneoplastic pemphigus. 
Lichen plano-pilaris is reported in association with dermatitis 
herpetiformis. 
 
Systemic:
60,61 
Thymoma, Myasthenia gravis, Diabetes mellitus, Hypertension, 
Ulcerative colitis and Hepatic disorders like primary biliary cirrhosis, 
chronic active hepatitis. 
 
 
 
 HISTOPATHOLOGY
1,20 
 Typical lesion of lichen planus shows compact hyperkeratosis, 
wedge-shaped hypergranulosis, irregular acanthosis, basal cell 
degeneration and dense band-like lympho-histiocytic infiltrate in upper 
dermis closely approximating the epidermis. Focal hypergranulosis is 
seen clinically as Wickham’s striae. Flattened rete ridges lead to ‘saw-
tooth’ appearance. Dermal melanophages are also present. Max-Joseph 
space is an artefact, present occasionally as focal dermo-epidermal 
separation. 
Colloid bodies (Civatte bodies/ Cytoid bodies) are seen as 
homogenous and eosinophilic structures in papillary dermis, about 20μm 
in diameter. These represent apoptotic basal cells or necrotic 
keratinocytes. 
 HYPERTROPHIC LICHEN PLANUS: Hyperkeratosis, acanthosis 
and papillomatosis are seen. In chronic cases, dermal fibrosis adjacent to 
inflammatory changes is present. 
 ATROPHIC LICHEN PLANUS: Epidermis is thinned out, but 
relative compact hyperkeratosis is still present. Rete ridges are 
completely effaced with relatively fewer colloid bodies. 
   
LICHEN PLANO-PILARIS: Infiltrate surrounding and sometimes 
permeating the base of hair follicles is present, along with follicular 
keratin plugging. 
 ACTINIC LICHEN PLANUS: Epidermis shows orthokeratosis 
and hypergranulosis. Prickle cell layer at center of the lesion is atrophic, 
with loss of rete pegs, but at borders it is acanthotic with saw-tooth 
appearance. Dense band-like infiltrate is present as in classical lichen 
planus. 
LICHEN PLANUS PIGMENTOSUS: Pigment incontinence 
extending deep into the reticular dermis. 
 BULLOUS LICHEN PLANUS: Sub-epidermal bulla, heavy 
dermal infiltrate, numerous colloid bodies. 
ORAL LICHEN PLANUS: Characteristic features are presence of 
parakeratosis and thinned-out epithelium. There are fewer colloid bodies 
and dense band-like infiltrate is composed mainly of plasma cells. 
 
 
 ELECTRON MICROSCOPY
1 
1. Basal keratinocytes show degenerative changes. 
2. Loss of desmosomes and disruption of tonofilaments in basal layer. 
3. Reduplication of basal lamina. 
4. Dermal infiltrate invades the epidermis and causes changes in 
lamina densa such as fragmentation, irregular folding and 
duplication. 
5. Colloid bodies are seen in papillary dermis. 
6. Split in lamina lucida in case of lichen planus pemphigoides. 
7. Separation between basal lamina and cytomembrane of basal 
keratinocytes in bullous lichen planus. 
 
IMMUNOFLUORESCENCE
1 
Direct immunofluorescence shows shaggy deposits of fibrinogen at 
dermo-epidermal junction. Occasionally granular or linear deposits of 
IgM (and rarely IgG or IgA) in basement membrane zone may be seen. 
Necrotic keratinocytes may be seen. In lichen plano-pilaris, fibrinogen 
 deposits around follicles and IgM and IgG or rarely C3 deposits at the 
level of infundibulum and isthmus are present. Lichen planus 
pemphigoides shows linear deposits of IgG and C3 along basement 
membrane zone of perilesional skin. Both direct and indirect 
immunofluorescence are negative in bullous lichen planus. 
 
COMPLICATIONS 
 Cicatricial alopecia: (Lichen plano-pilaris) 
 Erythroderma: (Generalized lichen planus) 
Pterygium 
 Twenty-nail dystrophy 
 Anonychia 
Deformity: (Ulcerative lichen planus of feet) 
Malignancy: (0.5-5% cases of oral lichen planus) 
 
 
 DIFFERENTIAL DIAGNOSIS
1,20 
 Classic lichen planus: Psoriasis, lichen simplex chronicus 
 Annular lichen planus: Granuloma annulare, dermatophytosis 
Hypertrophic lichen planus: Lichen simplex chronicus, prurigo 
nodularis, papular lichen amyloidosis, warts, kaposi sarcoma 
Linear lichen planus: Nevus unius lateris, lichen striatus 
Atrophic lichen planus: Lichen sclerosus et atrophicus, morphea 
Follicular lichen planus: Lichen nitidus 
Actinic lichen planus: Polymorphous light eruption 
Guttate lichen planus: Guttate psoriasis, secondary syphilis 
Lichen plano-pilaris of skin: Lichen nitidus, lichen spinulosus 
Lichen plano-pilaris of scalp: Cicatricial pemphigoid, alopecia 
areata, lupus erythematosus, inflammatory folliculitis 
Childhood lichen planus: Lichen nitidus, lichen striatus 
Nail involvement: Psoriasis, alopecia areata, onychomycosis 
 
 Mucosal lichen planus: Leukoplakia, oral pemphigus, candidiasis, 
secondary syphilis, lupus erythematosus, paraneoplastic pemphigus 
 
Lichenoid Drug Eruption: 
 
 Classic lichen 
planus 
Lichenoid drug 
eruption 
Lesion Small Large and scaly 
Wickham’s striae Present Absent 
Distribution Flexural 
Symmetrical over trunk 
and extremities; 
Photodistributed pattern 
Mucosal 
involvement 
Common Rare 
Alopecia Rare Common 
Colloid bodies 
seen higher in 
epidermis 
Absent Present 
Lymphocytic 
exocytosis 
Absent Present 
Parakeratosis Not seen Present 
Eosinophils Not present Present 
 
 
 
 TREATMENT 
 Lichen planus is usually benign and self-limiting. Various 
treatment modalities include: 
 Topical: Steroids, tacrolimus, pimecrolimus 
 Systemic: Steroids, retinoids, dapsone, anti-malarials, immuno-
suppressants, photochemotherapy, anti-histamines 
CUTANEOUS LICHEN PLANUS: 
 Topical: Steroids, tacrolimus, photochemotherapy 
 Systemic: Steroids, etretinate, acitretin, isotretinoin 
 Second-line: Cyclosporine, dapsone, hydroxychloroquine, 
azathioprine 
ORAL LICHEN PLANUS: 
 Topical: Steroids, Lidocaine, Tretinoin, Isotretinoin, Tacrolimus 
 Systemic: Steroids, Etretinate, Acitretin, Isotretinoin, Anti-candidal 
 Second-line: Cyclosporine, Griseofulvin, Thalidomide, Hydroxy-
chloroquine, Azathioprine, Cyclophosphamide, Photodynamic therapy 
OTHER VARIANTS: 
 Lichen planus pemphigoides: Doxycycline, Tetracycline, 
Nicotinamide 
 Generalized lichen planus: Interferon-α 2b, Metronidazole 
 Refractory cases: Cyclophosphamide, Methotrexate 
 CORTICOSTEROIDS 
 Corticosteroids are the drug of choice for treating lichen planus. 
These can be used in topical, systemic or intralesional formulations. 
  
Topical steroids: These are used in patients with mucosal and 
limited cutaneous involvement. Topical clobetasol propionate (0.05%) 
under occlusion leads to regression of lesions in most of the cases of 
limited cutaneous disease. Cortisone vaginal/rectal suppositories are used 
for mucosal lichen planus. Triamcinolone acetonide lozenges or 
betamethasone valereate aerosols can be used for oral lesions. 
 
 Systemic steroids: Oral steroids are indicated for extensive skin 
lesions, ulcerations over oral/vaginal mucosa, pterygium formation, 
bullous lichen planus and lichen planus of scalp. 
 Most commonly, prednisolone is used in dosage of 5-20 mg/day 
for 4-6 weeks and then gradually tapered over another 6 weeks. In 
patients requiring long duration of therapy, oral mini pulse can be given 
as oral betamethasone 5mg on two consecutive days per week. 
  
Intralesional steroids: Triamcinolone acetonide 5-10 mg/ml may be 
used in hypertrophic and nail lichen planus. 
 RETINOIDS 
 Topical retinoids: Isotretinoin gel (0.1%) and etretinate has been 
used in cases of oral lichen planus. 
  
Systemic retinoids: Acitretin is given as a dose of 30mg/day for 
eight weeks in severe cutaneous lichen planus and for two weeks in LP-
LE overlap syndrome. 
 
PHOTOCHEMOTHERAPY 
PUVA therapy may be used in generalized cutaneous and erosive 
oral lichen planus. Initial dose is 0.5-2 J/cm
2
 and it should not exceed 7 
J/cm
2
 in a single session, given for 3 times/week. 
 
 
IMMUNOSUPPRESSANTS 
 Cyclosporine is used in severe cutaneous, oral and nail lichen 
planus cases, at dosage of 3-10 mg/kg/day. Azathioprine is useful for 
generalized cutaneous involvement and lichen planus pemphigoides. 
Mycophenolate mofetil (1.5g twice a day) is also useful in oral and 
bullous forms. 0.1% tacrolimus ointment is useful in erosive oral lichen 
planus, as is 1% pimecrolimus cream. 
 
  
MISCELLANEOUS 
 Anti-malarials like hydroxychloroquine (200-400 mg/day) has 
been used for actinic and erosive lichen planus. Thalidomide can also be 
used for resistant cases of erosive lichen planus. Dapsone (200 mg/day) is 
useful in bullous and erosive types. Other drugs include griseofulvin 
(1g/day), phenytoin (100-200 mg/day) and metronidazole (500 mg twice 
daily). 
 Low-molecular weight heparin has anti-proliferative and 
immunomodulatory actions and is used as injection (3 mg/week) for 6-10 
weeks. 
 Interferon-α 2b can also be used in generalized cutaneous 
involvement, but it has also been implicated as a causative/aggravating 
factor of lichen planus. 
 Extracorporeal photopheresis and photodynamic therapy mediated 
methylene blue (MB-PDT) are used for oral lichen planus. 
 Split skin grafting has been used in ulcerative lichen planus of 
feet.
103 
 
 
 
 
  
COURSE AND PROGNOSIS
1 
 
 Lichen planus typically persists for 1-2 years, but course is 
unpredictable. It may follow a chronic relapsing course for many years. 
Generalized cutaneous lesions heal spontaneously and faster than limited 
cutaneous involvement. Lichen plano-pilaris is most chronic and 
progressive variant with permanent hair loss. Hypertrophic lichen planus 
also follows protracted course. Oral lichen planus has a mean duration of 
about 5 years. Usually, the duration of disease follows this order (shortest 
to longest): generalized, cutaneous, cutaneous + mucosal, mucosal, 
hypertrophic and lichen plano-pilaris. 
 
 Relapses occur in 15-20% cases and are more commonly reported 
in generalized disease. Serum neopterin level reflects the extent and 
progression of the lesions. Serum angiotensin converting enzyme (ACE) 
activity can be used for assessing the treatment response.
62
 
  
 HEPATITIS C VIRUS 
 
 Hepatitis C virus (HCV) was discovered in 1989.
72 
More than 170 
million people are infected with HCV worldwide.
69 
Although the 
incidence of HCV infection is much lower than that of hepatitis B virus 
(HBV) infection, the rate of chronically infected individuals is much 
higher.
71
 Morbidity associated with HCV infection is not only due to the 
sequelae of chronic liver disease, but also due to a variety of extrahepatic 
manifestations.
70 
It is not only the principal cause of post-transfusion 
chronic hepatitis, but is also associated with a number of cutaneous 
disorders other than lichen planus, like porphyria cutanea tarda, 
cryoglobulinemia, leukocytoclastic vasculitis and livedo reticularis. 
 Structure: Hepatitis C virus is a 55-65 nm, ss-RNA virus 
belonging to genus hepacivirus under the family flaviviridae, that 
replicates in hepatocytes and peripheral blood mononuclear cells. It 
consists of positive-sense, single-stranded, extremely variable
70
, RNA 
genome placed inside an icosahedral shell/nucleo-capsid and surrounded 
outside by a lipid envelope derived from host membrane. Viral envelope 
glycoproteins (E1 and E2) are embedded into this envelope. Genome of 
HCV consists of about 9600 nucleotide bases, which translates into very 
long protein containing about 3000 amino acids. 
 
  
 
 
 
 
40 
  
 Types:(Six genotypes)
70 
 Type 1- United States 
 Type 2- Not common 
 Type 3- India, Pakistan, Australia 
 Type 4- Middle East 
 Type 5- South Africa 
 Type 6- Asia 
  
Modes of transmission: HCV is mainly transmitted through blood 
transfusion (developing world) and intravenous drug usage (developed 
countries). Other modes include nosocomial, vertical and sexual 
transmission.
66 
  
Immunology: Both humoral and cell-mediated immunity play role 
in pathogenesis. The antibodies developing against viral structural and 
non-structural proteins are the basis for the assay. Cellular response 
includes action of CD4 and CD8 cells against HCV antigens. However, 
inspite of these defense systems of the host, reasons for chronicity of 
hepatitis C are attenuated antigenicity, restricted expression of MHC 
proteins in infected hepatocytes and emergence of virus quasispecies. 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
LIFE CYCLE OF HEPATITIS C VIRUS
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SOURCES OF INFECTION FOR HEPATITIS C 
 
 
 
 
 
  
 
 
 
 
 
NATURAL HISTORY OF HCV INFECTION
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GLOBAL BURDEN OF HEPATITIS C INFECTION
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 Clinical effects: 
HEPATITIS 
 CUTANEOUS: Lichen planus, cryoglobulinemia, porphyria 
cutanea tarda, leukocytoclastic vasculitis, livedo reticularis and Sjogren’s 
syndrome 
 
Diagnosis:  Two types of tests are available. Serological assays 
detect anti-HCV antibodies (ELISA and RIBA) and Molecular assays 
detect HCV RNA (Polymerase chain reaction). 
  
Enzyme Linked Immunosorbent Assay (ELISA): Antibodies to 
several HCV antigens are simultaneously detected. First generation 
ELISA uses recombinant antigen C100-3 derived from NS4 region of 
HCV genome. Second generation ELISA incorporates recombinant 
proteins from nucleo-capsid core (C22-3 and NS3 region). Third 
generation ELISA incorporates proteins from NS5 region and replaces 
some recombinant proteins with synthetic peptides. 
  
Radio Immunoblot Assay (RIBA): This is a supplementary test. 
Reactivity is confirmed by incubation with nitrocellulose strip that 
contains individual bands of recombinant or synthetic HCV proteins. 
 Polymerase Chain Reaction (PCR): This technique is very sensitive 
but complicated, expensive and time-consuming. Qualitative PCR used 
for confirmation of HCV infection detects fewer viral particles (< 50 
mRNA/ml) as compared to Quantitative PCR which detects > 500 
mRNA/ml. The latter is used for monitoring disease activity and response 
to treatment. 
  
Treatment: 
- Rest, diet and vitamins offer NO benefit 
- Pegylated interferon-alpha 
- Pegylated interferon-alpha 2a with ribavirin 
- Boceprevir or telaprevir 
- Sofosbuvir with interferon and ribavirin 
- Urso-deoxycholic acid 
- Hepatic iron removal 
- Liver transplant is last option 
- Alternative therapies- Milk thistle (Silybum marianum), ginseng, 
colloidal silver 
 
 
 
 LICHEN PLANUS IN HCV INFECTION 
 Lichen planus in HCV infection is mainly associated with class II 
HLA-DR6 allele. Various researchers have suggested that simultaneous 
appearance of lichen planus and HCV infection can be due to genetic, 
environmental, geographic or other factors.
74
 
 
Proposed mechanisms for this association are local induction of an 
immune response specific for HCV epitopes
70
, selective presentation of 
certain HCV-encoded peptides by HLA-DR6 molecules on surface of 
monocytes to the CD4+ cells, cytopathic replication of HCV in extra-
hepatic tissues, keratinocyte antigenic changes leading to cell-mediated 
response and lastly the auto-immunity. 
 
 Correlation of HCV infection with lichen planus has been reported 
to be statistically significant in various studies from Japan, Spain, 
Germany, USA, Italy and Europe. On the other hand, many researchers 
did not report any association. Most likely hypothesis describing this non-
homogeneity in results from different geographical areas is the regional-
based correlation. 
 
 
  
Many of the reports for lichen planus come from registries of 
hospitals or university affiliated clinics. These cannot represent the real 
situation in the general population. Difficulties in making a definite 
diagnosis for lichen planus make the interpretation even more complex. 
 
Estimation of the point prevalence of HCV infection in the general 
population and how well the control group was selected are other 
contributing variables which may lead to divergent results. Also, as HCV 
treatment, especially interferon-α, may provoke oral lesions similar to 
oral lichen planus, lack of information on the treatment status of enrollees 
with HCV infection in the studies makes summarizing the results 
challenging.
73 
Genetic factors and prevalence of certain HCV genotypes 
in certain geographical areas also influence the result. 
 
No correlation was observed between the viral load and HCV 
genotype and the likelihood of developing lichen planus in HCV-infected 
patients.
74 
Interestingly, co-infection with HIV decreases the possibility of 
lichen planus in HCV-infected patients, probably through 
immunodeficiency.
75
 
 
  
Overall, it can be concluded that HCV-infected patients may have 
increased risk of developing lichen planus or alternatively, patients with 
lichen planus may be at a higher risk for developing HCV infection. More 
prospective well-designed studies are necessary to clarify the issue. 
 
Clinically, lesions are similar to classic lichen planus, but mucosal 
involvement is more common especially erosive and reticular types. 
Lesions are symmetrically distributed over gingiva, tongue and lips. 
Mega et al reported three types of oral lichen planus: 1) Associated with a 
HCV infection (OLPHCV), 2) Oral lichen-contact sensitivity reaction 
(OLCSR), and 3) Idiopathic oral lichen planus (IOLP). 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
MATERIALS AND METHODS 
 
 
 
 
 
 
 
 
 
 
 
 STUDY DESCRIPTION: 
PLACE: Dept. of Dermatology, Govt. Stanley Medical College, Chennai 
DESIGN: Prospective, Observational 
TIME PERIOD: July 2013 to June 2014 
SAMPLE SIZE: 100 patients, 100 controls 
SOURCE OF PATIENTS: Patients attending Dermatology OPD of Govt. 
Stanley Medical College& Hospital Chennai, from July 2013 to June 
2014, clinically diagnosed as lichen planus (involving skin, mucous 
membrane or both). 
SOURCE OF CONTROLS: Voluntary blood donors being screened in 
Govt. Stanley Hospital, Chennai. 
 
INCLUSION CRITERIA: 
1) Male with Lichen planus  (>18years and <60 years of age) 
2) Female with Lichen planus (>18 years and <60 years of age) 
3) Patients willing to follow-up 
EXCLUSION CRITERIA: 
1) Patients taking drugs causing lichenoid eruptions like beta-
blockers, anti-malarials, diuretics, ACE inhibitors, chlorpropamide, 
simvastatin. 
2) Pregnant/Lactating woman 
 3) Pre-existing liver disease 
4) Past history of blood transfusion 
5) Intravenous drug users 
6) Blood dyscrasias like haemophilia 
7) Patients not willing for screening 
 
The study was conducted in accordance with ethical committee 
approval (ANNEXURE 3). Demographic data and detailed history for 
each patient (including duration and location of lesions, extent of 
involvement and any risk factors) were noted in a pre-designed proforma 
(ANNEXURE 1) after taking informed consent (ANNEXURE 2). 
Diagnosis was made by clinical examination. 
 
Following investigations were done in all patients: 
 Hemogram (Hb, TC, DC, ESR, Platelet count) 
 Liver function tests (S.Bil., SGOT, SGPT, SAP, STP, S.Alb.)  
 Renal function tests (S. urea and creatinine) 
 Random blood sugar 
 Hepatitis C antibody test (SD Bioline- Immunochromatography) 
 
 
 IMMUNOCHROMATOGRAPHIC HCV TEST 
(SD BIOLINE HCV 02FK10I) 
 
ONE STEP, RAPID IMMUNOCHROMATOGRAPHIC TEST FOR 
THE DETECTION OF ANTIBODY AGAINST HEPATITIS C 
VIRUS IN HUMAN SERUM, PLASMA OR WHOLE BLOOD 
 
Explanation of the test 
  
HCV diagnostic kit detects the presence of HCV antibodies in 
human serum by immunoassay. HCV genes are constructed for the 
expression of recombinant antigens in bacterium systems like E. coli. The 
major immunoreactive antigens of these proteins are Core, NS3, NS4 and 
NS5 regions of HCV genome. For diagnosis, these recombinant proteins 
are used as capture materials and coated on the membrane of the rapid 
test. Compared to the first generation HCV test using single recombinant 
antigens, multiple antigens using recombinant proteins have been added 
in new generation of tests to avoid non-specific cross-activity and to 
increase the sensitivity of test. 
 
 
 The SD BIOLINE HCV test is an immunochromatographic (rapid) 
test for the qualitative detection of antibodies specific to HCV, in human 
serum, plasma and whole blood. This test contains a membrane strip, pre-
coated with recombinant HCV capture antigen (core, NS3, NS4 and NS5) 
on test band region. The protein A-colloid gold conjugate and serum 
sample moves along the membrane chromatographically to the test region 
(T) and forms a visible line as the antigen-antibody-protein A gold 
particle complex forms with high degree of sensitivity and specificity. 
The SD BIOLINE HCV test window is clearly labelled- ‘T’ for ‘Test 
line’ and ‘C’ for ‘Control line’. Both the Test line and Control line in the 
result window are not visible before applying any samples. The Control 
line is used as a control and it should always appear if the test procedure 
is performed correctly. 
 
Materials provided 
1) SD BIOLINE HCV test device individually foil pouched with a 
desiccant 
2) Capillary pipette 
3) Assay diluent 
4) Package insert 
 
 Precautions/ Kit storage 
1) The test device should be stored at room temperature. 
2) The test device is sensitive to humidity as well as to heat. 
3) Perform the test immediately after removing the test device from 
pouch. 
4) Do not use it beyond the expiry date. 
5) The shelf-life of the kit is as indicated on outer package. 
6) Do not use the test kit if the pouch is damaged or seal is broken. 
7) Do not re-use the test device. 
8) Do not freeze. 
9) Assay Diluents contain sodium azide as a preservative. In case of 
contact with skin wash immediately, wear gloves and eye 
protection. 
 
Warnings 
1) For in vitro diagnostic use only. 
2) Wear protective gloves while handling specimens. 
3) Avoid splashing or aerosol formation. 
4) Clean up spills thoroughly using an appropriate disinfectant. 
5) Decontaminate and dispose of all specimens, reaction kits and 
potentially contaminated materials in a biohazard container. 
6) Do not mix and interchange different specimens. 
 7) Anticoagulants like heparin, EDTA and sodium citrate do not 
affect result. 
8) Use of hemolytic samples, rheumatoid factors-contained samples 
and lipidemic, icteric samples can lead to impair the results. 
9) Do not use any of the components beyond expiry date. 
10) Assay diluents contain sodium azide as a preservative. If 
these materials are to be disposed off through sink or other 
common plumbing system, flush with generous amount of water to 
prevent accumulation of potentially explosive compound. 
 
Specimen collection, storage and precaution 
1) Whole blood 
1) Collect the whole blood into the collection tube (containing 
anticoagulants such as heparin, EDTA and sodium citrate) by 
venipuncture. 
2) If blood specimens are not immediately tested, they should be 
refrigerated at 2-8 degree Celsius. 
3) When refrigerated, the specimens should be used within 3 days. 
4) For storage period longer than 3 days, freezing is recommended. 
They should be brought to room temperature prior to use. 
5) Using the blood specimens in the long-term keeping more than 3 
days can cause non-specific reaction. 
 2) Plasma or serum 
1) [Plasma]- Collect the whole blood into the collection tube 
(containing anticoagulants such as heparin, EDTA and sodium 
citrate) by venipuncture and then centrifuge blood to get plasma 
specimen. 
2) [Serum]- Collect the whole blood into the collection tube (Not 
containing anticoagulants such as heparin, EDTA and sodium 
citrate) by venipuncture, leave to settle for 30 minutes for blood 
coagulation and then centrifuge blood to get serum specimen of 
supernatant. 
3) If plasma or serum specimens are not tested immediately, they 
should be refrigerated at 2-8 degree Celsius. For storage period 
longer than 2 weeks, freezing is recommended. They should be 
brought to room temperature prior to use. 
4) Plasma or serum specimens containing a precipitate may yield 
inconsistent test results. 
 
Test procedure 
1) Remove the test device from the foil pouch, place it on a flat, dry 
surface. 
2) Using a capillary pipette, add 10μl of serum, plasma or blood 
specimen (up to the black line) into the sample well(s). 
 3) Add 4 drops (about 120μl) of assay diluent into sample well(s). 
4) Interpret test results in 5-20 minutes. 
5) Reading too late can give false results. 
 
 
Interpretation of results 
1) A color band will appear in the left section of the result window. 
This band is control line (C). 
2) Color band appearing in the right section of result window is test 
line (T). 
3) Negative Result: The presence of only one color band (C) in the 
result window. 
4) Positive Result: The presence of two color bands (C and T) in the 
result window. 
5) Invalid Result: If the control band (C) is not visible in result 
window, result is considered invalid and the specimen must be 
retested using a new test device. 
 
  
  
Limitations of the test 
1) Negative result does not preclude the possibility of HCV infection. 
2) Specimens repeatedly tested positive should be retested using 
another testing method. 
3) A definitive clinical diagnosis should not be based on the results of 
a single test, but should only be made by the physician after all 
clinical and laboratory findings have been evaluated. 
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RESULTS 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
AGE DISTRIBUTION 
 
Age (Years) No. of cases Percentage 
18-20 Males- 7 
Females- 11 
18 
21-30 Males- 13 
Females- 16 
29 
31-40 Males- 8 
Females- 16 
24 
41-50 Males- 9 
Females- 6 
15 
51-60 Males- 11 
Females- 3 
14 
Total 100 100 
 
In the present study, most of the cases were in the age group 21-30 
years and minimal number was seen at extremes of age group. 
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SEX DISTRIBUTION 
 
Sex No. of cases Percentage 
Male 48 48 
Female 52 52 
Total 100 100 
 
There was slight female preponderance. (M:F = 1:1.08) 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
Sex distribution 
Males
Females
  
 
OCCUPATION 
 
Occupation No. of patients Percentage 
Housewife 28 28 
Student 29 29 
Farmer/ Labourer 16 16 
Others 27 27 
Total 100 100 
 
In our study, most of the patients were house-wives (Female 
group), students (Younger age group) and farmers/ labourers (Elderly 
patients). Remaining cases were working in different fields, including 
driver, constable, teacher and nurse. 
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DURATION OF DISEASE 
 
Duration No. of cases Percentage 
<1 month 9 9 
1-3 months 37 37 
3-6 months 29 29 
6months- 1year 15 15 
>1 year 10 10 
Total 100 100 
 
Maximum duration of illness was 2 years, but most of patients 
were having the disease since 1-3 months (37%). 
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SYMPTOMS 
 
Symptoms No. of cases Percentage 
Asymptomatic 7 7 
Mild itching 15 15 
Moderate itching 45 45 
Severe itching 33 33 
Total 100 100 
 
In study, only 7 cases were found to be asymptomatic. On the other 
hand, 78 patients had moderate to severe itching. 
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RISK FACTORS 
 
Risk factor No. of cases Percentage 
Smoking 15 15 
Alcohol 19 19 
Stress 10 10 
Surgery 7 7 
 
19 lichen planus patients were alcoholic and 15 of them were 
smokers. Out of these 34 cases, 8 were smoker as well as alcoholic. 10 
patients gave history of emotional stress and 7 cases had undergone a 
surgery in the past. 
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PREVIOUS MEDICAL HISTORY 
 
History No. of cases Percentage 
Jaundice 4 4 
Hypertension 18 18 
Diabetes Mellitus 21 21 
 
21 patients were diabetic and 18 were hypertensive. 4 patients had 
jaundice in the past. 
 
 
 
 
 
 
 
  
 
 
 
PREVIOUS MEDICAL HISTORY 
 
 
 
 
 
 
 
 
No. of cases 
Jaundice
Hypertension
Diabetes mellitus
  
 
CLINICAL VARIANTS 
 
Variant No. of cases Percentage 
Classic 76 76 
Hypertrophic 8 8 
Linear 3 3 
Follicular 2 2 
Actinic 6 6 
Oral 3 3 
Genital 2 2 
Total 100 100 
 
Classical lichen planus was the most common clinical form of 
disease encountered in our study (76%). Hypertrophic lichen planus was 
seen in 8 patients and the least common variants were follicular and 
genital lichen planus, with 2 cases each. 
 
 
  
 
 
CLINICAL VARIANTS 
 
 
 
 
 
 
 
 
 
No. of cases 
Classic
Hypertrophic
Linear
Follicular
Actinic
Oral
Genital
  
SITES OF INVOLVEMENT 
 
Site No. of cases Percentage 
Upper limb 72 72 
Lower limb 80 80 
Trunk 17 17 
Neck 3 3 
Scalp 2 2 
Genital 2 2 
Oral 29 29 
Nails 11 11 
 
In present study, most commonly, upper and lower limbs were 
affected. Trunk was involved in 17 cases, nails in 11 cases and oral 
mucosa in 29 patients.  
Only 2 cases showed scalp and genital involvement, each. 
 
 
 
  
 
 
SITES OF INVOLVEMENT 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
No. of cases 
No. of cases
  
 
 
ASSOCIATION WITH HCV ANTIBODIES 
 
 Study Group Control Group 
No. of cases 100 100 
Seropositive cases 0 2 
 
Out of 100 voluntary blood donors, two were HCV seropositive, 
but none of the lichen planus patients tested seropositive for HCV 
antibodies. 
 
 
 
 
 
 
 
  
 
 
 
 
 
DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 Prevalence 
 The present study was conducted over a period of one year (July 
2013 to June 2014), during which 40,107 new patients attended Skin 
OPD at Govt. Stanley Medical College & Hospital. Out of these, 100 
patients (>18 years and <60 years of age), diagnosed clinically as lichen 
planus were taken up for study. So, prevalence of lichen planus is about 
0.25%. 
 The prevalence reported worldwide
6
 is <1%.Other studies include 
0.28% by Anbar
76
 and 0.38% by Bhattacharya
14
 (India). 
Age distribution 
 In present study, most of the cases were in age group 21-40 years 
(53%). In the study by Kachhawa et al, 47% cases were in this age 
group.
78
 
Sex distribution 
 Slight female preponderance was noted in our study.(52%) 
Predilection for male sex has been reported by Kachhawa et al
78
, 
but female preponderance was shown in study by Boyd et al.
6 
 
 Occupation 
 Most of the patients in or study were house-wives (28%), students 
(29%) and farmers/ labourers (16%). 
Naldi et al
79
 study showed predominance of manual workers 
(46%). 
Duration of disease 
 Maximum duration of illness in our study was 2 years, and 37% of 
patients were having the disease since 1-3 months. 
This is in accordance with the study by Sehgal et al, in which most 
of cases were having disease since 2-3months.
11 
Symptoms 
 78 patients had moderate to severe itching, 15 had mild itching, 
and 7 cases were asymptomatic. 
According to previous studies, moderate to severe itching has been 
reported in 95% cases (Sehgal et al)
11
 and 73% cases (Kachhawa et al)
78
. 
But, Fine et al concluded that severity of itching varies with extent of 
involvement. 
  
Risk factors 
 In present study, 19 lichen planus patients were alcoholic and 15 of 
them were smokers. Out of these 34 cases, 8 were both smoker and 
alcoholic. 10 patients gave history of emotional stress and 7 cases had 
undergone a surgery in the past. 
Naldi et al had reported smoking in 36% cases and alcohol as risk 
factor in 67% cases.
79 
Previous medical history 
 In our study, 21 patients were diabetic, 18 were hypertensive and 4 
patients had jaundice in the past. 
This is supported by studies of Kachhawa et al
78
 (Hypertension in 
12% cases) and Naldi et al
79
 (Diabetes in 5% cases). But is in contrast to 
the study by Anjana et al
102
, where no association was seen with diabetes 
or hypertension. 
 
 
 Clinical variants 
 Classic lichen planus was the most common clinical form of 
disease encountered in our study (76% cases). Hypertrophic lichen planus 
was seen in 8 patients and the least common variants were follicular and 
genital lichen planus, with 2 cases each. 
Sites of involvement 
 Our study showed upper and lower limbs (72-80%) as the most 
common sites of involvement in lichen planus. Trunk was involved in 
17% cases, nails in 11% cases and oral mucosa in 29% patients. Only 2 
cases showed scalp and genital involvement, each. The result is like that 
of study by Kachhawa et al
78
 (Lower limb involvement in 62% cases). 
Study by Ebrahimi also showed oral involvement in 29% of patients 
having cutaneous lichen planus.
77 
Anbar et al
76
 reported involvement of both skin and mucosa in 65% 
cases and only mucosal lesions in 15-35% cases. In other studies, 
involvement of skin, both skin and mucosa, and mucosa alone was seen 
in 98%, 68% and 7% cases (Stojanovic et al)
81
, 71%, 20% and 12% cases 
(Sehgal et al)
11
, respectively. 
 
  
Koebner’s phenomenon 
 17% of subjects in present study showed Koebner’s phenomenon. 
This is similar to the result of studies by Fine et al
80
 and Boyd et al
6
. 
Nail changes 
In our study, 11% patients had nail changes. Kachhawa et al
78
 
found nails to be involved in 6.4% cases. But in study by Sehgal et al
11
, 
none of the cases had nail involvement. 
  
  
Correlation with HCV 
S.No. Study Place Year 
Lichen planus 
cases associated 
with anti-HCV 
antibodies 
1. Tanei et al
82 
Japan 1995 37.8% 
2. Sanchez-Perez et al
83 
Spain 1996 20% 
3. Imhof et al
84 
Germany 1996 16% 
4. Narayan et al
85 
India 1997 2.66% 
5. Zahra Ghodsi et al
86 
Iran 1998 4.8% 
6. Chuang et al
87 
USA 1999 55% 
7. Tucker et al
88 
England 1999 0 
8. Kirtak et al
89 
Turkey 2000 6.8% 
9. Daramola et al
90 
Nigeria 2000 15.8% 
10. Asaad Tonsi et al
91 
Makkah 2000 26.3% 
11. Leslie et al
92 
USA 2001 17% 
12. Prabhu et al
95 
India (Calicut) 2002 0 
13. Garg et al
100 
Nepal 2002 0 
14. Lodi et al
93 
Italy 2004 19.1% 
15. Bokor-Bratic
94 
Serbia 2004 0 
16. Cunha et al
96 
Brazil 2005 1.5% 
17. Ghaderi et al
97 
Iran 2006 4.1% 
18. Das et al
98 
India (Kolkata) 2006 1.92% 
19. Yarom et al
99 
Israel 2006 1.5% 
20. Stojanovic et al
81 
Slovenia 2008 1.2% 
 
 
 
 
  
 
 
 
 
CONCLUSION 
 
 
 
 
 
 
 
 
 
 
 
 The study shows that lichen planus commonly affects young 
adults, with almost equal male-female ratio. Prevalence of lichen planus 
is 0.25%. 
Most common age group affected is 21-40 years. 
Slight female preponderance is seen (M:F = 1:1.08). 
Maximum duration is 2 years. But most of patients (37%) have 
disease since 1-3 months. 
Moderate to severe itching is seen in 78% cases. Only 7% cases are 
asymptomatic. 
Alcohol (19%) and smoking (15%) are the most common risk 
factors. 
Diabetes and hypertension are associated in 21% and 18% patients, 
respectively. 
Most common clinical variant is classic type of lichen planus 
(76%), followed by hypertrophic type (8%). 
The most common sites involved are the extremities, with lower 
limb in 80% cases and upper limb in 72% cases. 
 Along with cutaneous involvement, 26% of the cases show oral 
changes. But 3% show only oral lesions (Reticular type) without any 
cutaneous lesions. 
11% patients have nail changes. 
Koebner’s phenomenon is seen in 17% patients. 
2% of controls (voluntary blood donors) showed HCV 
seropositivity, but none of the lichen planus patients showed positive test 
for anti-HCV antibodies. 
The present study shows no association between lichen planus 
and hepatitis C infection. Based on this result, it can be concluded 
that anti-HCV antibody testing is not necessarily required in lichen 
planus patients having no risk factors for HCV infection in this 
geographic region. 
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ANNEXURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
PROFORMA 
(ANNEXURE 1) 
 
NAME:     
AGE: 
SEX: 
OCCUPATION: 
ADDRESS: 
 
 
CHIEF COMPLAINTS: 
 
HISTORY & DURATION OF PRESENT ILLNESS: 
 
 
PAST MEDICAL HISTORY: 
 
RISK FACTORS: 
 
EXAMINATION: 
SITE: 
CLINICAL VARIANT: 
WICKHAM STRAIE: 
KOEBNER PHENOMENON: 
NAIL CHANGES: 
ORAL INVOLVEMENT: 
 
 
  
DIAGNOSIS: 
 
INVESTIGATIONS: 
CBC:  HB: 
 TC: 
 DC: 
 ESR: 
 PLATELET: 
 BLOOD GLUCOSE: 
 
LFT: S. BIL: 
 SGOT: 
 SGPT: 
 ALP: 
 STP: 
 S. ALB: 
 
RFT: S. UREA: 
 S. CREATININE: 
 
HCV SEROLOGY: 
 
 
 
 
 
  
 CONSENT FORM 
(ANNEXURE 2) 
 
Mr/Miss/Mrs: 
Age/Sex: 
Address: 
 
Phone: 
I undersigned Mr/Miss/Mrs.___________________________ have been 
explained regarding above said study in my regional language. 
I have been informed that this study will be done by Dr. Nishant Gupta. 
I further state that I have carefully read and understood all the 
information provided in this form and with full conscious mind, I hereby 
give my consent to be involved in this study. 
I also give consent to take my clinical photograph required for the study 
purpose. 
 
Signature/Right Thumb Impression of patient: 
 
Signature/Thumb impression of the parent/guardian (In minors): 
 
Witness: 
Name:      Signature: 
Date: 
 
 
  
 
 
 
 
  
KEY TO MASTER CHART 
M- Male 
F- Female 
D- Diabetes mellitus 
H- Hypertension 
Sm- Smoker 
St- Emotional stress 
Sg- Surgery in the past 
Al- Alcoholic 
J- Past history of jaundice 
UL- Upper limb 
LL- Lower limb 
T- Trunk 
N- Neck 
HT- Hypertrophic lichen planus 
 
 
 
  
 
 
 
 
 
 
 
 
MASTER CHART 
 
 
 
 
 
 
 
 
 
 
 
 MASTER CHART 
S. 
No. 
Name Age Sex Occupation Duration 
Risk 
Factors 
Site WS KP 
Clinical 
Variant 
Nail 
changes 
Oral 
involvement 
Anti- HCV 
Antibody 
1 Renuga 38 F Housewife 4months D UL,LL - - Classic - + - 
2 Devaki 29 F Student 2months - UL,LL - + Classic - - - 
3 Uma 18 F Student 1month J LL - - Classic - - - 
4 Thangaraj 30 M Driver 1month St,Al UL,LL - - Classic - - - 
5 Vasugi 35 F Housewife 3months - LL - - HT - - - 
6 Ganesh 42 M Driver 4months Sm,Al UL,LL,T - - Classic - - - 
7 Devi 26 F Housewife 2months - UL,LL - + Classic - - - 
8 Jayanthi 56 F Housewife 10months D,H UL,LL,T + - Classic + + - 
9 Ruban 55 M Farmer 1year Sm,Al,D UL,LL - - Classic + - - 
10 Nirmala 28 F Housewife 1month - LL - + Classic - - - 
11 Hemchandran 35 M Business 5months St,Al UL,LL - + Classic - - - 
12 Devendran 40 M Clerk 6months Al UL,LL - - Classic - + - 
13 Selvarani 18 F Student 1month - LL - + Linear - - - 
14 Sarath 19 M Student 1month - UL,LL - - Classic - - - 
15 Lalitha 28 F Housewife 3months - LL - - Classic - - - 
16 Jamaal 38 M Labourer 4months Sm,Al UL,LL - - Classic - - - 
17 Paneerselvam 42 M Clerk 8months Sm,H UL,LL - - Classic - - - 
18 Selvaraj 49 M Business 9months Al, D UL,LL - - Classic - + - 
19 Nagesh 45 M Farmer 5months St,Al UL,LL - - Classic - - - 
20 Kousalya 30 F Teacher 1month - UL,N - - Actinic - - - 
21 Balraj 46 M Constable 3months Al,D UL,LL - - Classic - - - 
22 Thambiraj 21 M Student 1month - T - + Linear - - - 
23 Ileyas 36 M Job 2months Sg, D UL,LL - - Classic - - - 
 24 Venkatesan 60 M Farmer 2years Al,H LL,T - - HT + + - 
25 Vignesh 21 M Student 20days - UL - - Classic - - - 
MASTER CHART (Contd.) 
S.No. Name Age Sex Occupation Duration 
Risk 
Factors 
Site WS KP 
Clinical 
Variant 
Nail 
changes 
Oral 
involvement 
Anti- HCV 
Antibody 
26 Rakib 20 M Student 1month - LL - - Classic - - - 
27 Bhavani 23 F Student 2months - UL - + Actinic - - - 
28 Paavai 60 F Labourer 1.5years Sm,D UL,LL - - HT + + - 
29 Pradalaya 18 F Student 1month - UL,LL - - Classic - - - 
30 Jailaxmi 20 F Student 20days - LL - - Classic - - - 
31 Gangan 60 M Ex-constable 2years Sm,D UL,LL - - Classic - - - 
32 Gomati 40 F Housewife 7months H UL,LL - + Classic - + - 
33 Selvi 30 F Housewife 2months - UL,LL - - Classic - - - 
34 Babu 46 M Clerk 6months Sg, H UL,Scalp - - Follicular - + - 
35 Ravi 28 M Business 2months - LL - - Classic - - - 
36 Raj 28 M Job 4months - LL,Penis - + Genital - - - 
37 Venkatesh 60 M Business 1year Sm,Al,St,D UL,LL + - Classic - + - 
38 Srinivasan 37 M Labourer 6months - UL,LL - - Classic - + - 
39 Arumugam 50 M Farmer 1.5years Al,D LL,T - - HT - + - 
40 Abdul 29 M Job 2months St UL - - Actinic - - - 
41 Kamatchi 19 F Student 1month - LL - - Classic - - - 
42 Selvi 23 F Student 4months - UL,LL - - Classic - - - 
43 Radha 22 F Student 20days J UL - + Classic - - - 
44 Nagarani 40 F Housewife 9months Sg, H UL,LL + - Classic + + - 
45 Abinesh 21 M Student 1month - LL - - Classic - - - 
46 Praveen 18 M Student 15days J LL - - Classic - - - 
 47 Vimala 30 F Housewife 5months - UL,LL - - Classic - + - 
48 Karthiga 22 F Student 3months - UL,LL - + Classic - - - 
49 Panduranga 56 M Labourer 2years Sm, D LL,T - - HT + + - 
50 Sharmila 38 F Housewife 1year D UL,LL - - Classic + + - 
MASTER CHART (Contd.) 
S. 
No. 
Name Age Sex Occupation Duration 
Risk 
Factors 
Site WS KP 
Clinical 
Variant 
Nail 
changes 
Oral 
involvement 
Anti- HCV 
Antibody 
51 Seshini 18 F Student 1month - UL,LL - - Classic - - - 
52 Madhan 19 M Student 15days - LL,Penis - + Genital - - - 
53 Kamalama 46 F Housewife 1.5years Sg, D UL,LL,T + - Classic - + - 
54 Deepan 21 M Job 1month - UL,N - - Actinic - - - 
55 Ravi 48 M Driver 6months St,H Oral - - Oral - + - 
56 Dinesh 19 M Student 2months - UL - - Classic - - - 
57 Amvardeen 49 M Farmer 7months Sm,Al,H UL,LL - - Classic - - - 
58 Dhanam 48 F Housewife 8months - UL,LL,T - - HT + + - 
59 Tamizhselvi 48 F Housewife 6months D UL,LL,T - - Classic - - - 
60 Hemavathy 39 F Housewife 6months - Oral - - Oral - + - 
61 Devakumar 32 M Job 3months St,Sm UL,LL - + Classic - - - 
62 Thangalingam 55 M Farmer 2years Al,H UL,LL - - Classic + + - 
63 Kanchal 35 F Housewife 3months D LL - - Classic - - - 
64 Priya 19 F Student 10days - UL,N - - Actinic - - - 
65 Jayanthi 22 F Student 2months - T - - Linear - - - 
66 Vinita 19 F Student 1month J UL,LL - - Classic - - - 
67 Rajalaxmi 20 F Student 20days - UL - - Classic - - - 
68 Velangani 28 F Housewife 6months - UL,LL + - Classic - - - 
69 Roopchandran 30 M Business 5months St,H UL,LL - - Classic - - - 
 70 Imtiaz 20 M Student 2months - LL - - Classic - - - 
71 Manoharan 55 M Farmer 2years Sm,H UL,LL - - Classic - - - 
72 Sakthivel 60 M Farmer 1year Al, D,H UL,LL,T - - Classic - + - 
73 Prabhavathy 18 F Student 20days - UL - - Classic - - - 
74 Raja 21 M Student 6months - UL,LL - - Classic - - - 
75 Lakshmi 38 F Housewife 1year D UL,LL - - Classic + + - 
MASTER CHART (Contd.) 
S. 
No. 
Name Age Sex Occupation Duration 
Risk 
Factors 
Site WS KP 
Clinical 
Variant 
Nail 
changes 
Oral 
involvement 
Anti- HCV 
Antibody 
76 Kamladevi 40 F Housewife 5months Sg UL,LL - - Classic - - - 
77 Ahmadnesha 48 F Housewife 4months H UL,LL - - Classic - + - 
78 Albert 24 M Business 4months Sm,St UL - - Actinic - - - 
79 Naveen 18 M Student 15days - UL - + Classic - - - 
80 Palani 59 M Labourer 1.5years Sm,Al,D,H UL,LL,T + - Classic + + - 
81 Madhavan 33 M Driver 6months Sm,Al Scalp - + Follicular - - - 
82 Balkish 25 F Clerk 2months - LL - - Classic - - - 
83 Gayathri 24 F Student 3months - UL,LL - - Classic - - - 
84 Lavanya 19 F Student 1month - LL - + Classic - - - 
85 Vijaylaxmi 37 F Constable 8months - UL,LL - - Classic - + - 
86 Vijaya 35 F Housewife 6months - UL,LL,T - - Classic - - - 
87 Shanthi 60 F Housewife 2years D,H, Sg UL,LL,T - - HT - + - 
88 Abdul 21 M Constable 1month - LL - - Classic - - - 
89 Rukmani 36 F Nurse 1month D UL,LL - - Classic - - - 
90 Sumathi 35 F Housewife 4months - Oral - - Oral - + - 
91 Shanthi 50 F Housewife 6months - UL,LL - - Classic - - - 
92 Dhanpal 57 M Conductor 1year Sm,Al,H LL - - HT - - - 
 93 Rani 33 F Housewife 5months - UL,LL - - Classic - - - 
94 Vijaylaxmi 38 F Housewife 1year St,H UL,LL - - Classic - - - 
95 Ramamurthy 30 M Clerk 4months - UL,LL - + Classic - - - 
96 Dulkanam 50 F Housewife 6months Sg,H UL,LL - - Classic - + - 
97 Kalpana 29 F Housewife 2months - UL,LL - - Classic - - - 
98 Nithya 35 F Labourer 4months - UL,LL - - Classic - - - 
99 Rathnavelu 32 M Labourer 6months - UL,LL,T - - Classic - - - 
100 Moorthy 55 M Labourer 2years Al,D UL,LL,T - - Classic - + - 
 
